Proceedings of the National Academy of Sciences · 1989 · 134 citations · 15 references
Life SciencesImmunologyAutoimmunityImmunotherapyNeuroimmunologyAntigen PresentationAntigen RecognitionAutoimmune DiseasesHistocompatibility AntigensMajor Histocompatibility ComplexT Cell ActivationAntigen-specific T Cell ResponsesExperimental Autoimmune EncephalomyelitisImmunodominant AntigensMajor Histocompatibility Complex GenesPeptide-based ImmunomodulationPeptide-based ImmunotherapyT Cell Response InductionT-cell Mediated Immunity
Two synthetic immunodominant and nonencephalitogenic peptides of myelin basic protein, N1-20 and AcN9-20, effectively compete with an encephalitogenic peptide, AcN1-11, in an in vitro T-cell response restricted by class II major histocompatibility complex products (I-Au). These mutant peptide constructs, which do not occur in nature, also compete with the self-antigen for the in vivo induction of T cells primed with the encephalitogen AcN1-11. By using these nonpathogenic competitor peptides, it is possible to prevent the development of a prototypic T-cell-mediated autoimmune disease, experimental allergic encephalomyelitis. These results suggest possibilities for the utilization of competitor peptides for therapy of T-cell-mediated autoimmune diseases linked to specific major histocompatibility complex genes.
15
Binding of immunogenic peptides to Ia histocompatibility molecules
Bruce Babbitt, Paul M. Allen, Gary R. Matsueda et al. · Nature · 1985 · 1.2K citations
T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis
Scott S. Zamvil, Dennis J. Mitchell, Anne Moore et al. · Nature · 1986 · 466 citations